With a market cap of $16.8 billion, Hologic, Inc. (HOLX) is a global medical technology company focused on developing and supplying diagnostic products, medical imaging systems, and surgical solutions ...

ARLINGTON, Va.--(BUSINESS WIRE)--The National Evaluation System for health Technology (NEST), an initiative of the Medical Device Innovation Consortium (MDIC), is pleased to welcome Hologic, a leading ...

On Friday, the FDA warned against using Hologic Inc.’s (NASDAQ:HOLX) BioZorb Marker products and urged healthcare facilities to return all unused lots. This follows Hologic’s voluntary recall of the ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX), a global champion of women’s health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc.

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today the U.S. launch of the SuperSonic™ MACH 40 ultrasound system, expanding the Company’s suite of ultrasound technologies ...

The Food and Drug Administration issued a warning letter to Hologic Inc. (NASDAQ:HOLX), citing violations in the manufacturing and reporting processes for its BioZorb product line. The letter, ...

Hologic HOLX offers a wide range of diagnostic products to help in the screening and diagnosis of human disease. Although the performance of the Diagnostics segment in recent quarters has been ...

Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has cleared Hologic’s first gastrointestinal (GI) pathogen detection tests. The FDA ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Marlborough-based medical ...

HOLX's Global Women's Health Index shows STI testing stagnates at 10%, leaving nearly 2 billion women at risk despite gains in other screenings.

Hologic nears its $76 buyout price as Diagnostics faces headwinds, tariffs hurt, and the stock trades at a sector premium.